News

Neutrophils, once considered simple foot soldiers of innate immunity, are now recognized as complex players in cancer.
Some GOP lawmakers in Congress have heralded the $50 billion rural program as a health care victory. But it’s still unclear which hospitals, clinics, and other providers would receive money and how ...
The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...
Counsell said once a week he and bench coach Ryan Flaherty will wonder out loud how Sandberg hit 13 triples at Wrigley Field ...
Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.
Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.
In recently reported case studies, nemolizumab, approved for two indications associated with itch, has been reported to be ...
Belzutifan is a hypoxia-inducible factor-2α inhibitor that is US FDA approved for the treatment of VHL disease-associated renal cell carcinoma (RCC), CNS hemangioblastomas, or pancreatic ...
Bristol Myers Squibb acknowledged that a phase III trial of luspatercept (Reblozyl) plus a Janus kinase inhibitor for ...
ACROBiosystems is breaking the chain of chronic suffering and safeguarding intestinal health. Learn how in this article.
Benign and cancerous calcium phosphate deposits that may look identical on a mammogram have distinct differences in their ...
Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...